Phase 3 · NCT06859268
TRIUMPH-6
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity
Active, not recruitingVerified
Trial registry record
What this means
The registry describes the study design and status. This label does not mean results have been reported.
Figure / record sourceLast verified 23 Oct 2026
Registry record
Trial details
- Trial
- TRIUMPH-6
- ClinicalTrials.gov ID
- NCT06859268
- Indication
- Obesity
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Eli Lilly and Company
- Enrolment
- 643
- Status
- Active, not recruiting
- Interventions
- Drug: Retatrutide; Drug: Placebo
- Comparator
- Placebo
- Eligible ages
- 18 Years – No maximum
- Locations
- 53 sites · Canada, United Kingdom, United States
- Study start
- 5 Mar 2025
- Primary completion
- 1 Apr 2028
- Study completion
- 1 Apr 2028
Verification
- Last verified
- 23 Oct 2026
- Source
- ClinicalTrials.gov
- Registry last updated
- 3 Mar 2026
Endpoints
Primary
Percent Change from Baseline in Body Weight
Secondary
Change from Baseline in Waist Circumference; Percentage of Body Weight Reduction Achieved at Week 80 that is Maintained at Week 116; Change from Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)